To investigate the maternal-fetal transfer of tobramycin (TBM) and its distribution in the fetus, a single dose of 2 mg/kg was administered intramuscularly to 35 pregnant patients (13 first trimester, 22 second trimester) 0.5 to 34 h before hysterectomy. TBM concentration was assayed microbiologically in maternal serum, fetal tissues (placenta, brain, lung, liver, and kidney), and fluids (amniotic, cerebrospinal fluid [CSF], urine, and serum). Mean maternal serum half-life (1.54 h) and mean peak serum concentration ofTBM were within ranges reported for nonpregnant adults. In fetal serum, half-life was 5.2 h, and TBM levels did not exceed 0.58 ,g/ml. For intervals up to 34 h, the mean TBM concentration in placental tissues was 1.4 gg/g. Concentration differences related to fetal maturation were found for fetal CSF, amniotic fluid, and fetal kidney. No antimicrobial activity was found in the fetal CSF of >16 weeks' gestation. TBM was present predominantly in the second trimester amniotic fluid specimens. Fetal kidney concentrations reached 7.2 ug/g at 34 h after maternal drug administration. Higher TBM concentrations were related to advanced maturation ofthe fetal kidney. Second trimester fetal urine concentrations for TBM ranged from 0.1 to 3.4 gg/ml, and the fetal urinary half-life was 3.7 h. Knowledge of fetal pharnacology is essential for weighing the fetal benefits or risks of antimicrobial therapy for the infected gravid patient.
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Tobramycin (tobramycin sulfate [Nebcin] ; TBM) is one of the more recently identified components of the nebramycin complex introduced by Stark et al. (12) in 1967. Nebramycin is known to have eight factors, of which TBM is factor 6 . These are water-soluble, basic compounds that fall into the general class of aminoglycosidic antibiotics produced by fernentation biosynthesis with Streptomyces tenebrarius.
TBM sulfate was released for clinical use in the United States in 1975. Its particular effectiveness is in the inhibition of Pseudomonas species, including those resistant to other aminoglycosides. The clinical benefits and risks of maternal therapy for the conceptus are often overlooked because of a paucity of human data. This study was undertaken to investigate the maternal-fetal transfer of TBM and its distribution in the human fetus of 9 to 20 weeks' gestation.
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MATERIALS AND METHODS
Thirty-five healthy gravid patients were admitted from July 1972 to June 1973 for elective therapeutic abortion and sterilization by hysterectomy. After informed consent was obtained, a single 2-mg/ kg intramuscular dose of TBM was administered to the patients before surgery. Thirteen patients were in the first (I) trimester, and 22 were in the second (II) trimester. The time interval between administration of TBM to the patient and the clamping of the uterine arteries at delivery will be referred to as an "interval" in this report. This interval varied from 2 to 20.5 h for the trimester I patients and from 40 min to 34 h for trimester II patients. Thirty-four fetuses, from 9 to 20 weeks' gestation, were available for sampling.
Gestational age was calculated from day 1 of the last normal menstrual period. When the date of the last menstrual period was uncertain, fetal weight and foot length were used to estimate gestational age (13) .
Maternal serum samples were taken before the intramuscular administration and at 1, 2, 4 and 8 h after the injection of TBM. A delivery time sample was obtained at the time of uterine artery clamping.
After surgical removal of the uterus, its contents were dissected under sterile conditions. Total amniotic fluid volume was measured, and an aliquot was taken for sampling. The placenta was separated, weighed, and sampled. The fetus was weighed and then measured for crown-heel, crownrump, and foot length. Fetal blood, urine, and cerebrospinal fluid (CSF) samples were obtained by needle aspiration. Fetal brain, lung, liver, and kidney tissue samples were acquired by dissection. Complete sampling ofall fetal tissues and fluids was not technically possible in fetuses of less than 12 weeks' gestation. All specimens were frozen at -20°C until time of TBM assay.
TBM concentrations in maternal and fetal tissues and fluids were determined in duplicate by microbiological assay (1) with a modified standard cylinder plate method and Bacillus subtilis (ATCC 6633) on AM11 agar (Difco, 0593-01, Detroit, Mich.). The lowest detectable TBM concentrations were the following: 0.06 ,ug/ml for fetal urine and in maternal and fetal serum; 0.1 ,ug/ml for fetal CSF and amniotic fluid; 0.4 ,ug/g for placenta; and 0.08 ,ug/g for fetal brain, kidney, lung, and liver. Control curves of fetal tissues and fluids were made from a pool of six antibiotic-free fetuses.
STATISTICS
The two-sample rank test (the Mann-Whitney U test) was used to measure the significance of differences between any two groups of data, and significance levels were judged at P < 0. 
RESULTS
Maternal serum. Maternal serum concentrations of TBM at 1, 2, 4, and 8 h, plus those at delivery time only up to an 11-h interval, are shown in Fig. 1 . TBM was not detected in the delivery time maternal serum samples ofthe 15 gravid patients who delivered after the 11-h interval ( Table 1) . A mean maternal peak serum concentration of 4.0 ,g/ml occurred at 1 h and tl2 was 1.54 h. Since no significant difference by trimester was found for t1,2 or peak serum concentrations, the 35 patients could be considered as one group and are represented by the regression line in Fig. 2a (r = 0.93).
Placenta. TBM appeared in the first placental sample at 40 min and remained detectable until the last sample, taken at 34 h (Table 1) . In all but 2 of the 29 samples, concentrations were above 1 ug/g, with an overall mean concentration of 1.4 ug/g. Although not significant, a definite trend toward increasing TBM concen- (Fig. 2d) . TBM was present as early as 2 h and as late as 34 h in 24 of 27 samples analyzed. At more than 9 h after maternal antibiotic injection, 53% of the trimester II fetal kidney samples had TBM concentrations of 3 Ag/g or more, a clinically therapeutic concentration. Two 20-week fetal kidney samples had 6.6 and 7.2 ,ug of TBM per g at 17 and 34 h, respectively. A significant correlation be- tween the interval from maternal injection and fetal kidney concentration can be seen in Fig.  2d (r = 0.54). When gestational age was related to the fetal kidney TBM concentration, the correlation coefficient improved to r = 0.79. An even more significant correlation coefficient ofr = 0.82 was found when multiple regression analysis was used to relate (i) TBM concentration in fetal kidney, (ii) the interval after maternal TBM injection, and (iii) the weeks of gestation (Fig. 3) .
Fetal urine. Fetal urine was available from 19 fetuses of more than 12 weeks' gestation. TBM appeared promptly in the first sample taken at 40 min. The highest concentration, 3.4 ,ug/ml, occurred at an interval of 2.5 h. After this peak, a steady decline in concentration was observed. A tl2 of3.7 h was calculated (r = 0.92; Fig. 2e ). No relationships could be established between fetal urine and fetal kidney TBM concentrations or gestational age.
Amniotic fluid. In fetuses older than 13 weeks' gestation, antimicrobial activity in amniotic fluid was first detected at a 4-h interval. An overall mean TBM concentration of 0.25 ,ug/ml was sustained until the 21.6-h interval.
In trimester II samples, TBM was found in fetal urine before it appeared in amniotic fluid samples (Fig. 2f) . At or beyond a 4-h interval, only three of eight trimester I amniotic fluid samples revealed TBM activity, whereas all of 20 trimester II samples had aminoglycoside present, indicating a significant relationship to gestational age (Table 1) .
CSF and other tissues. Of 27 fetal brain samples, none contained TBM in detectable 10- concentrations. In the fetal CSF, very low TBM concentrations (0.1 to 0.7 ,ug/ml) were found at the 2-to 20-h interval in 9 of 15 fetuses of less than 17 weeks' gestation. No TBM was detected in the 16 fetuses of 17 weeks' gestation or more (Table 1) . TBM could not be detected in any of the 32 fetal lung or 33 fetal liver specimens.
DISCUSSION
Our data, from the single sampling of 34 different fetuses in the early weeks of pregnancy, demonstrated enough consistency to establish biological curves and provide a meaningful indicator of the kinetics and distribution of TBM in the conceptus.
During the first 20 weeks of pregnancy, the maternal plasma volume increases 30% (2), and renal plasma flow and glomerular filtration rate increase 30% to 50% (6) . In spite of these changes, the mean maternal peak serum concentration and serum t1/2 were found to be within the ranges reported. for healthy, nonpregnant adults when similar doses were used (3, 11) .
In the placental tissue samples from fetuses in the first half of pregnancy, a mean tissue TBM concentration of 1.4 ,g/g was maintained for at least 24 h; this concentration bore no relationship to presence of TBM in maternal serum. If we can assume that micrograms per grams of tissue are equivalent to micrograms per milliliter of body fluids for bacteriological inhibition, then TBM may prove useful in the treatment of placental infections, since in vitro bacterial inhibitory concentrations of TBM range from 0.4 to 0.8 ug/ml for Staphylococcus aureus and 0.8 to 3.1 ug/ml for Pseudomonas species, Escherichia coli, and Klebsiella pneumoniae (9, 10) . Investigations addressing the question of whether higher placental concentrations can be produced by larger or repetitive doses may define a limited or linear capacity to handle TBM.
After it had crossed the placenta to the fetus, TBM was cleared from the fetal serum within 17 h, with a tl2 of 5.25 h. Kaplan and co-workers (5) reported that the TBM serum t12 for small premature infants is 8. Fetal renal tissue concentrations of TBM were high and were found to increase significantly for as long as 34 h, whereas both fetal serum and urine concentrations steadily declined to nondetectable levels by 17 and 21.6 h, respectively. Luft and Kleit (7) reported prolonged renal parenchymal accumulation in adult rats after a single dose of several aminoglycosidic antibiotics. Dissection of the adult rat kidneys revealed 85% of the TBM to be in the cortex, which consists mostly of proximal tubules and where histological evidence of gentamicin toxicity has been described. With advancing gestational age, the human fetal kidney has a more defined cortical structure (14) . This may explain the significant differences in TBM concentration in the fetal kidneys of 10 weeks' gestation as compared with those 20 weeks of age. The absolute or relative tissue concentration of TBM that would cause fetal renal toxicity is not known for any stage offetal maturation. One wonders whether TBM, a potentially nephrotoxic aminoglycoside, could be used more safely in trimester I because of the lower concentrations found in the younger fetal kidney or whether it could be equally or more toxic because of the greater degree of renal immaturity. If, in our studies, the fetal kidney could attain such high and sustained levels after administration of a single therapeutic dose to the gravid patient, then might higher renal tissue concentrations be reached when multiple doses of TBM are administered? This has been shown to occur with other antibiotics by Philipson and co-workers (8) . They reported a considerably higher increase in fetal kidney concentration of both erythromycin (500 mg) and clindamycin (450 mg) after multiple doses compared with single doses of the same agents administered to pregnant patients.
Thirty percent of the human fetal glomeruli appear to be relatively mature histologically by 16 weeks' gestation (14) . Fetal urine concentrations of TBM were 5 to 10 times greater than those found in simultaneous fetal serum samples. If TBM is primarily excreted by glomerular filtration, our results are consistent with active renal glomerular TBM excretion in the fetus of 13 or more weeks' gestation.
TBM did not appear in the amniotic fluid until it was present in the urine; this is consistent with the premise that the presence of the antibiotic in amniotic fluid is primarily related to renal excretion. One might expect TBM to accumulate in amniotic fluid; however, rather inexplicable static levels were found in amniotic fluid, which is known to undergo a dynamic turnover.
Although it has been traditional to sample body fluids for evidence of drug concentrations in a toxic range, our findings in the fetal kidney give rise to a serious skepticism about the equatability ofsuch an approach since, with the longer intervals, the fetal kidney had increasing mean concentrations of TBM, whereas fetal serum and urine levels were decreasing to undetectable amounts. Tissue sampling for drug levels may be a more appropriate, although usually inaccessible, approach to extending the understanding of the pharmacology of certain therapeutic agents. Further investigation of the perinatal pharmacology of this and other drugs is imperative to obtain the data necessary for treating the infected gravid patient and her fetus with the increasing number of available antimicrobials.
